Article
Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.
All News
Article
The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines.
Article
MMWR has reported on a July 2020 survey study from 1,009 Health Resources and Services Administration–funded health centers showing that urban Health centers were more likely to provide virtual visits than those in rural areas.
Dr. John Cush
Tweet
Join us this March for RheumNow Live! Sign up via the link below.
https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI
Dr. John Cush
Tweet
Study of 2050 Northern Italian arthritis clinic pts; where 1.1-1.4% of population developed COVID-19. Steroid use was independently associated with increased COVID risk (adj OR 1.23 to 3.20). But Rx w/ ts/bDMARDs had reduced risk (adj OR 0.46). https://t.co/cLXdpzda9t
Dr. John Cush
Tweet
Rifampin is safest! 2 RCTs of 6485 latent TB pts compared 9 mos of isoniazid vs 4 mos of rifampicin. RIF had half the adverse events compared to INH; roughly half the rate of rash (1.5% v 2.7%); No grade 3-4 hepatotoxicity w/ RIF, compared 6%) w/ INH https://t.co/6Nz0zeP8ik
Dr. John Cush
Tweet
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zJJp8
Dr. John Cush
Tweet
Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/8IQRHoPqBl https://t.co/5MkvEKcNJg
Dr. John Cush
Tweet
#Bestof2020
Plaquenil Does Not Protect Lupus Patients from COVID-19
https://t.co/R5S7phlqYb https://t.co/HDlDfE98RQ
Dr. John Cush
Tweet
23% of RA patients have moderate-to-severe Obstructive Sleep Apnea (AHI ≥ 15) - study of RA patients 199 patients underwent PSG, OSA is more common in RA than in the general population, but there is no relationship with disease activity. https://t.co/wNasW3AerN
Dr. John Cush
Tweet
Surveys/interviews w/ 1010 patients suggest Telehealth worked best for routine & familiar health issues w/ pre-existing clinical relationship. Telehealth less suitable when examination was needed, when Dx was unknown, when patients prefered F2F visis https://t.co/QZYBzxyGz6
Dr. John Cush
Tweet
Risk of venous thromboembolism is increased in ankylosing spondylitis patients. Study of 7190 pt shows a 2 fold risk, higher in the first year - risks for PE (HR 2.88), DVT (HR 2.20) and VTE overall (HR 2.10 ) were increased. https://t.co/TIhlKuRw8S
Dr. John Cush
Tweet
#Bestof2020 Update on Polymyalgia Rheumatica and Giant Cell Arteritis
https://t.co/8Kxts1X43H https://t.co/j06SFRxQ3m
Dr. John Cush
Tweet
NEJM: Actemra Studied in COVID pneumonia and shown to improve outcomes (mech ventilation or death ;12 vs 19.3%) but did not improve survival (10.4 vs 8.6%). 389 hospitalized pts randomized 2:1 to get 2 IV doses Actemra +SOC vs SOC alone https://t.co/BdslXFXOYD
Dr. John Cush
Tweet
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zs8xA
Dr. John Cush
Tweet
Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/8IQRHoPqBl
Dr. John Cush
Tweet
23% of RA patients have moderate-to-severe Obstructive Sleep Apnea (AHI ≥ 15) - study of RA patients 199 patients underwent PSG, OSA is more common in RA than in the general population, but there is no relationship with disease activity. https://t.co/wNasW3AerN
Dr. John Cush
Tweet
Great read from early last year-Physicians estimate that about 15% of their patients - they dread to see; as they cause aversion, fear, despair or even malice. Washington post reviews how demanding patients should and should not be with their physicians. https://t.co/etCclBXFNu
Dr. John Cush
Tweet
Plasmapheresis Indications : TTP, HUS, Cryoglobulinemia, Hyperviscosity, Myasthenia gravis, Goodpastures, Catastrophic APL Syn, Chr inflamm demyelinating polyneuropathy, Removal of drugs/toxins, Alveolar hemorrhage, ANCA vasculitis (questionable) https://t.co/8TBExIx0Kx
Dr. John Cush
Tweet
ENTRACTE trial studied the risk of major adverse CV events (MACE) in 3080 RA pts Rx with tocilizumab (TCZ) vs etanercept (ETN), and found no increased risk of MACE in TCZ patients compared to ETN (HR 1.05 (95% confidence interval 0.77–1.43). https://t.co/KpOEeVAAxx
